Ahmed El Kaffas

Dr. Ahmed El Kaffas


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
AZAli Zifan
Ali Zifan
KZKatelyn Zhao
Katelyn Zhao
MLMadilyn Lee
Madilyn Lee
ZPZihan Peng
Zihan Peng
LRLaura Roney
Laura Roney
CSClaude B. Sirlin
Claude B. Sirlin
Background: Liver ultrasound segmentation is challenging due to low image quality and variability. While deep learning (DL) models have been widely applied for medical segmentation, generic pre-configured models may not meet the specific requirements for targeted areas in liver ultrasound. Quantitative ultrasound (QUS) is emerging as a promising tool for liver fat measurement; however, accurately segmenting regions of interest within liver ultrasound images remains a challenge. Methods: We introduce a generalizable framework using an adaptive evolutionary genetic algorithm to optimize deep learning models, specifically U-Net, for focused liver segmentation. The algorithm simultaneously adjusts the depth (number of layers) and width (neurons per layer) of the network, dropout, and skip connections. Various architecture configurations are evaluated based on segmentation performance to find the optimal model for liver ultrasound images. Results: The model with a depth of 4 and filter sizes of [16, 64, 128, 256] achieved the highest mean adjusted Dice score of 0.921, outperforming the other configurations, using three-fold cross-validation with early stoppage. Conclusions: Adaptive evolutionary optimization enhances the deep learning architecture for liver ultrasound segmentation. Future work may extend this optimization to other imaging modalities and deep learning architectures.

4 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
CDChristoph Frank Dietrich
Christoph Frank Dietrich
MBMichael Blaivas
Michael Blaivas
VCVito Cantisani
Vito Cantisani
XCXinwu Cui
Xinwu Cui
Yi DongYi Dong
Yi Dong
Christian JenssenChristian Jenssen
Christian Jenssen
Background: Handheld ultrasound (HHUS) is increasingly used in point-of-care imaging because of its portability, accessibility, versatility, and comparatively low cost. Methods: This structured narrative technical review evaluated current HHUS technology, image quality and functionality, clinical applications, regulatory considerations, and future perspectives using recent literature, comparative studies, technical sources, and previous EFSUMB/WFUMB position papers. A structured SWOT analysis informed draft recommendations, which underwent three rounds of scientific discussion and revision by a 17-member international multidisciplinary expert panel. Each of the seven final recommendations was subsequently voted on separately, with consensus predefined as ≥80% agreement. Results: While HHUS devices are increasingly suitable for routine clinical use, further standardization, clinician training, and regulatory alignment are essential for widespread adoption. Conclusions: HHUS can expand access to focused ultrasound imaging, particularly in point-of-care and resource-limited settings. Its appropriate use requires task-specific device selection, adequate training, quality assurance, and recognition of its limitations compared with comprehensive ultrasound systems.

26 August 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
SMSTAVROS MELEMENIDIS
STAVROS MELEMENIDIS
AKAnna Stephanie Kim
Anna Stephanie Kim
JVJenny M. Vo-Phamhi
Jenny M. Vo-Phamhi
Edward Elliot GravesEdward Elliot Graves
Edward Elliot Graves
AKAhmed El Kaffas
Ahmed El Kaffas
DHDimitre Hristov
Dimitre Hristov
We report a low-cost protocol and platform for whole-abdomen 3D dynamic contrast-enhanced ultrasound (DCE-US) imaging in mice using a clinical matrix-array transducer. Background/Objectives: This platform addresses common limitations of preclinical ultrasound systems. In particular, these systems often lack real-time volumetric and molecular imaging capabilities. Methods: Using a modified silicone cup and water bath configuration, mice with dual subcutaneous tumors were imaged in vivo on a clinical EPIQ 7 system equipped with an X6-1 transducer. Results: Intravenous administration of targeted microbubbles enabled high-resolution, contrast-mode 3D imaging at multiple time points. Volumetric reconstructions captured both tumors and surrounding anatomy in a single scan, while time–intensity curves and Differential Targeted Enhancement (DTE) analysis revealed greater microbubble uptake in irradiated tumors, consistent with elevated P-selectin expression. Conclusions: This standardized imaging platform enables whole-abdomen molecular DCE-US in preclinical studies, facilitating intra-animal comparisons of vascular and molecular features across lesions or organs.

12 December 2024 in arXiv
Verified
Preprint
Open access
PDF file
SMStavros Melemenidis
Stavros Melemenidis
AKAnna Stephanie Kim
Anna Stephanie Kim
JVJenny Vo-Phamhi
Jenny Vo-Phamhi
EGEdward Graves
Edward Graves
AKAhmed El Kaffas
Ahmed El Kaffas
DHDimitre Hristov
Dimitre Hristov
Background: This protocol introduces an ultrasound (US) configuration for whole-body 3D dynamic contrast-enhanced ultrasound (DCE-US) imaging in preclinical applications. The set-up relies on a clinical abdominal matrix US probe to enable mice imaging beyond current preclinical systems that are generally unable to capture whole-body volumetric and dynamic imaging. We demonstrate via this protocol the feasibility of volumetric contrast-enhanced and molecular 3D imaging in the entire lower body of mouse, as well as the capability of imaging multiple lesions in the same animal simultaneously with a single contrast bolus injection. Methods: We modified a silicone cup with a 101.6 mm inner diameter and 6.4 mm wall thickness, to a height of 76.2 mm and cut out a rectangular side window (12.7 mm x 15.9 mm) at the lower part of the cup. Mice were positioned with their head and the two front legs outside of the cup while the rest of the body remained inside the cup and submerged under water; the edges around the mouse's body in contact with the cup's wall were sealed with Vaseline to prevent water leakage, and the cup was filled with warm water to maintain the mouse's body heat. Imaging was conducted using a portable clinical ultrasound system (EPIQ 7 Philips) with an abdominal matrix-array transducer (PM mode, X6-1) inserted into the top of the cup, and positioned to visualize the entire of the mouse's abdomen. The mice were imaged before and after the injection of P-selectin-targeted microbubbles. Results: Here, in nude mice with two adjacent tumors, we demonstrate that a commercially available clinical matrix transducer can be utilized to achieve whole-body 3D DCE-US and molecular US imaging, as well as capture independent qualitative and quantitative information from several lesions or organs at different locations in the animal, through a single bolus injection.

1 September 2026 in ADVANCED ULTRASOUND IN DIAGNOSIS AND THERAPY
Verified
Journal Article
Open access
PDF file
BOBryan Oronsky
Bryan Oronsky
DLDandan Li
Dandan Li
MWMorgan Wang
Morgan Wang
JVJenny M. Vo-Phamhi
Jenny M. Vo-Phamhi
SCScott Caroen
Scott Caroen
AKAhmed El Kaffas
Ahmed El Kaffas
Background and Purpose: Tumor blood vessels are abnormal and contribute to therapy resistance. RRx-001, an NLRP3 inhibitor, has been shown to remodel tumor vascular properties, enhancing the effects of cytotoxic or immune-promoting agents. However, optimizing timing and dosing of combined treatment regimens is challenging on a patient-by-patient basis; tools for longitudinal imaging to guide such treatment strategy are necessary. Our aim was to evaluate the feasibility of 3D dynamic contrast-enhanced ultrasound (3D DCE-US) to detect acute and subtle tumor perfusion changes following RRx-001 therapy in both mice and humans. Methods: RRx-001 was administered intraperitoneally at varying doses to determine its effect on perfusion in a mouse model of colon cancer. Blood flow and volume were assessed semi-quantitatively using 3D DCE-US within hours and at subsequent time-points. Additionally, we assessed 3D DCE-US in three patients enrolled in a Phase 2 RRx-001 clinical trial (NCT02096354) by imaging them longitudinally. Results: In mice (n = 38), 6 mg/kg RRx-001 led to a 1.5% increase in AUC (P = 0.02) and MTT at 24 hours; 12 mg/kg showed no acute effect. In patients (n = 3), 66 mg weekly dosing produced variable perfusion changes within hours to days. Two patients with stable disease showed transient perfusion increases (survival 9-15 months); one with progressive disease showed early perfusion loss (survival 4 months). No grade 3/4 toxicities occurred. Conclusion: These findings highlight the potential of 3D DCE-US as a noninvasive, bedside tool for real-time monitoring of RRx-001-induced perfusion changes, supporting the feasibility of personalized dosing strategies in both preclinical and clinical settings.